指南与共识其他结缔组织病

儿童关节炎与风湿病研究联盟关于难治性中度重度幼年皮肌炎生物制剂改善病情抗风湿药共识治疗方案

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2024-08-14

儿童关节炎与风湿病研究联盟生物制剂工作组采用病例调查、共识框架和名义群体技术,为难治性中度重度幼年皮肌炎制定了四种生物制剂改善病情抗风湿药共识治疗方案,包括肿瘤坏死因子α抑制剂(阿达木单抗或英夫利西单抗)、阿巴西普、利妥昔单抗和托珠单抗;在76名应答者中,共识达成率为93%(67/72),加权平均显示应答者最可能使用利妥昔单抗,其次为阿巴西普、肿瘤坏死因子α抑制剂和托珠单抗。

要点

  • 为难治性中度重度幼年皮肌炎制定四种生物制剂改善病情抗风湿药共识治疗方案。
  • 共识达成率为93%(67/72),涵盖患者特征、评估、结局指标和随访。
  • 加权平均显示最可能使用利妥昔单抗,其次为阿巴西普、肿瘤坏死因子α抑制剂和托珠单抗。

核心结论

  • 采用共识方法为难治性中度重度幼年皮肌炎制定了生物制剂改善病情抗风湿药共识治疗方案。

研究设计与样本

  • 儿童关节炎与风湿病研究联盟幼年皮肌炎研究委员会生物制剂工作组采用病例调查、共识框架和名义群体技术制定共识治疗方案。

主要发现

  • 提出了四种生物制剂改善病情抗风湿药共识治疗方案:肿瘤坏死因子α抑制剂(阿达木单抗或英夫利西单抗)、阿巴西普、利妥昔单抗和托珠单抗。
  • 每种共识治疗方案在给药剂量和/或途径上有不同选择。
  • 在76名应答者中,对提出的共识治疗方案达成共识的比例为93%(67/72)。
  • 加权平均显示,应答者最可能使用利妥昔单抗,其次为阿巴西普、肿瘤坏死因子α抑制剂和托珠单抗。

关键数值与推荐

  • 共识达成率为93%(67/72),涵盖患者特征、评估、结局指标和随访。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease-modifying antirheumatic drugs (bDMARDs). METHODS: The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case-based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM. RESULTS: Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow-up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab. CONCLUSION: CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry-based prospective comparative effectiveness studies.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Tarvin SE, Sherman MA, Kim H, et al. Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2024. PMID: 38937134. doi:10.1002/acr.25393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。